Access the full text.
Sign up today, get DeepDyve free for 14 days.
Raymond Sawaya, M. Hammoud, Derek Schoppa, Kenneth Hess, Shu Wu, Wei Shi, D. Wildrick (1998)
Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors.Neurosurgery, 42 5
Yiwu Huang, R. Hayes, S. Wertheim, E. Arbit, R. Scheff (2001)
Treatment of refractory recurrent malignant glioma with adoptive cellular immunotherapy: a case report.Critical reviews in oncology/hematology, 39 1-2
J. Cairncross, K. Ueki, Magdelena Zlatescu, D. Lisle, D. Finkelstein, R. Hammond, J. Silver, P. Stark, D. MacDonald, Y. Ino, D. Ramsay, D. Louis (1998)
Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.Journal of the National Cancer Institute, 90 19
Sun-jin Kim, H. Uehara, T. Karashima, D. Shepherd, J. Killion, I. Fidler (2003)
Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice.Clinical cancer research : an official journal of the American Association for Cancer Research, 9 3
N. Laperriere, L. Zuraw, G. Cairncross (2002)
Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 64 3
W. Yung (2000)
Temozolomide in malignant gliomas.Seminars in oncology, 27 3 Suppl 6
H. Kurzen, S. Schmitt, H. Näher, T. Möhler (2003)
Inhibition of angiogenesis by non-toxic doses of temozolomideAnti-Cancer Drugs, 14
A. Beutler, M. Banck, D. Wedekind, H. Hedrich (1999)
Tumor gene therapy made easy: allogeneic major histocompatibility complex in the C6 rat glioma model.Human gene therapy, 10 1
Sumeer Lal, Michel Lacroix, P. Tofilon, G. Fuller, R. Sawaya, F. Lang (2000)
An implantable guide-screw system for brain tumor studies in small animals.Journal of neurosurgery, 92 2
P. Giglio, V. Levin (2004)
Cyclooxygenase-2 Inhibitors in Glioma TherapyAmerican Journal of Therapeutics, 11
R. Hayes, E. Arbit, M. Odaimi, S. Pannullo, R. Scheff, Dmitriy Kravchinskiy, C. Zaroulis (2001)
Adoptive cellular immunotherapy for the treatment of malignant gliomas.Critical reviews in oncology/hematology, 39 1-2
S. Gately, R. Kerbel (2003)
Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis.Progress in experimental tumor research, 37
C. Rüegg, O. Dormond, A. Mariotti (2004)
Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis.Biochimica et biophysica acta, 1654 1
M. Lacroix, D. Abi‐Said, D. Fourney, Z. Gokaslan, W. Shi, F. DeMonte, F. Lang, I. McCutcheon, S. Hassenbusch, E. Holland, K. Hess, C. Michael, Daniel Miller, R. Sawaya (2001)
A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival.Journal of neurosurgery, 95 2
(2001)
Interferonalpha2a and 13-cis-retinoic acid with radiation treatment for high-grade glioma
B. Grobben, P. Deyn, H. Slegers (2002)
Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasionCell and Tissue Research, 310
Yang Cao, S. Prescott (2002)
Many actions of cyclooxygenase‐2 in cellular dynamics and in cancerJournal of Cellular Physiology, 190
S. Kang, C. Ryu, S. Jeun, Chun-Kun Park, Hyung-Jin Shin, Jong Kim, M. Kim, Joon-ki Kang (2004)
Lymphokine activated killer cells from umbilical cord blood show higher antitumor effect against anaplastic astrocytoma cell line (U87) and medulloblastoma cell line (TE671) than lymphokine activated killer cells from peripheral bloodChild's Nervous System, 20
D. Nam, Kwan Park, Chaehwa Park, Y. Im, Mi-hyun Kim, Sangjun Lee, Seung-Chyul Hong, H. Shin, Jong-Hyun Kim, W. Eoh, T. McDonnell (2004)
Intracranial inhibition of glioma cell growth by cyclooxygenase-2 inhibitor celecoxib.Oncology reports, 11 2
P. Graham (1993)
Meta‐analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adultsCancer, 72
N. Kobayashi, N. Allen, N. Clendenon, L. Ko (1980)
An improved rat brain-tumor model.Journal of neurosurgery, 53 6
(1999)
Procarbazine and highdose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study
W. Yung, R. Albright, J. Olson, R. Fredericks, K. Fink, M. Prados, M. Brada, A. Spence, R. Hohl, W. Shapiro, M. Glantz, H. Greenberg, R. Selker, N. Vick, R. Rampling, H. Friedman, P. Phillips, J. Bruner, N. Yue, D. Osoba, S. Zaknoen, V. Levin (2000)
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapseBritish Journal of Cancer, 83
Tadahisa Shono, P. Tofilon, Janet Bruner, Olubunmi Owolabi, Frederick Lang (2001)
Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations.Cancer research, 61 11
Shaoqing Tang, Yu-guang Gao, J. Ware (1999)
Enhancement of Endothelial Cell Migration and in Vitro Tube Formation by Tap20, a Novel β5 Integrin–Modulating, Pkcθ-Dependent ProteinThe Journal of Cell Biology, 147
A. Kardosh, M. Blumenthal, W. Wang, Thomas Chen, A. Schonthal (2004)
Differential Effects of Selective COX-2 Inhibitors on Cell Cycle Regulation and Proliferation of Glioblastoma Cell LinesCancer Biology & Therapy, 3
R. Prayson, Elias Castilla, M. Vogelbaum, G. Barnett (2002)
Cyclooxygenase-2 (COX-2) expression by immunohistochemistry in glioblastoma multiforme.Annals of diagnostic pathology, 6 3
L. Tentori, C. Leonetti, A. Aquino (1995)
Temozolomide reduces the metastatic potential of Lewis lung carcinoma (3LL) in mice: role of alpha-6 integrin phosphorylation.European journal of cancer, 31A 5
G. Gliki, R. Abu-Ghazaleh, S. Jezequel, C. Wheeler-Jones, I. Zachary (2001)
Vascular endothelial growth factor-induced prostacyclin production is mediated by a protein kinase C (PKC)-dependent activation of extracellular signal-regulated protein kinases 1 and 2 involving PKC-delta and by mobilization of intracellular Ca2+.The Biochemical journal, 353 Pt 3
B. Jeremic, B. Miličić, D. Grujicic, A. Dagović, J. Aleksandrovic, N. Nikolić (2004)
Clinical Prognostic Factors in Patients With Malignant Glioma Treated With Combined Modality ApproachAmerican Journal of Clinical Oncology, 27
E. Newlands, M. Stevens, S. Wedge, R. Wheelhouse, C. Brock (1997)
Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials.Cancer treatment reviews, 23 1
I. Parney, Susan Chang (2003)
Current Chemotherapy for GlioblastomaThe Cancer Journal, 9
M. Napolitano, F. Keime-Guibert, A. Monjour, C. Lafitte, A. Améri, P. Cornu, P. Broët, J. Delattre (2004)
Treatment of Supratentorial Glioblastoma Multiforme with Radiotherapy and a Combination of BCNU and Tamoxifen: A Phase II StudyJournal of Neuro-Oncology, 45
T. Joki, O. Heese, D. Nikas, L. Bello, Jianping Zhang, S. Kraeft, N. Seyfried, T. Abe, Lanren Chen, R. Carroll, P. Black (2000)
Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398.Cancer research, 60 17
S. Cha, E. Knopp, G. Johnson, A. Litt, J. Glass, M. Gruber, Stanley Lu, D. Zagzag (2000)
Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin.AJNR. American journal of neuroradiology, 21 5
L. Stewart (2002)
Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trialsThe Lancet, 359
The purpose of this study was to determine whether a combination treatment of temozolomide with celecoxib is effective in the rat orthotopic glioma model. After stereotactic injection of C6/LacZ rat glioma cells into the Sprague Dawley rat brain, the rats were randomly assigned to four treatment groups (group 1, control treatment; group 2, celecoxib (25 mg/kg p.o. everyday) alone; group 3, temozolomide (7.5 mg/kg i.p. for 5 days at 2nd week) alone; group 4, a combination of celecoxib and temozolomide). Rats were sacrificed 18 days after treatment, and the body weight, tumor volume, tumor cell proliferation, microvessel densities, and apoptosis were evaluated. There was a significant reduction of tumor volume in combination group compared to control or single-agent therapy. The median tumor volume was estimated to be 111.5 mm3 (control), 65.0 mm3 (celecoxib), 71.8 mm3 (temozolomide) and 18.7 mm3 (combination). In the combination group, there was increased tumor cell apoptosis as well as decreased microvessel density and tumor cell proliferation relative to the control and single-agent therapy (P<0.05). Collectively, the data suggest that the combination celecoxib and temozolomide may provide a novel and effective approach to the treatment of glioblastoma.
Oncology Reports – Spandidos Publications
Published: Jan 1, 2006
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.